Get the Stockscreener App
19.88
0.45%
0.09
After Hours:
19.89
0.01
+0.05%
Pharvaris Nv stock is traded at $19.88, with a volume of 69,306.
It is up +0.45% in the last 24 hours and up +12.95% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
See More
Previous Close:
$19.79
Open:
$19.535
24h Volume:
69,306
Relative Volume:
0.74
Market Cap:
$1.27B
Revenue:
-
Net Income/Loss:
$-143.59M
P/E Ratio:
-7.0407
EPS:
-2.8236
Net Cash Flow:
$-119.47M
1W Performance:
-0.85%
1M Performance:
+12.95%
6M Performance:
+12.95%
1Y Performance:
+15.99%
1-Day Range:
$19.26
$20.49
1-Week Range:
$19.19
$20.95
52-Week Range:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
19.88 | 1.27B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Key resistance and support levels for Pharvaris N.V.Trend Analysis for Safer Market Entries - Newser
Volatility clustering patterns for Pharvaris N.V.Free Buy Low Sell High Stock Watch - Newser
When is Pharvaris N.V. stock expected to show significant growthPost Market Growth Plan To Watch Now - jammulinksnews.com
Will Pharvaris’s (PHVS) Fresh $175M Boost Shift Its Ownership Balance and Strategic Direction? - simplywall.st
Is it the right time to buy Pharvaris N.V. stockBest Dividend Data Feed To Watch Now - jammulinksnews.com
Is Pharvaris N.V. a Top Dividend Stock to Watch in 2025Pattern Recognition Based Market Move Prediction - Newser
Does Pharvaris N.V. show high probability of reboundFree Community Shared Smart Money Signals - Newser
What institutional investors are buying Pharvaris N.V. stockRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
What Fibonacci levels say about Pharvaris N.V. reboundFree Weekly Chart Analysis With Entry Advice - Newser
Pharvaris N.V. Earnings Report Breakdown: What Investors Should KnowEntry Timing Tracker with Alert Accuracy - Newser
Using data tools to time your Pharvaris N.V. exitFree Strong Buy With Technical Confidence - Newser
Pharvaris N.V. stock outlook for YEARAccurate Forecast System with AI Support - Newser
What makes Pharvaris N.V. stock price move sharplyFree Step-by-Step Stock Investment Guide - Newser
Pharvaris N.V. stock momentum explainedTechnical Insight Guide for Safer Trades - Newser
Pharvaris N.V. Uptrend in Early Stages Indicators Say YesDaily Volume Spike Trading Signals Detected - metal.it
How Interest Rate Changes Impact Pharvaris N.V. Stock PerformanceFree Risk Controlled Short Term Trade Plans - Newser
Combining machine learning predictions for Pharvaris N.V.AI Stock Movement Forecast with Accuracy - Newser
Why is Pharvaris N.V. stock attracting strong analyst attentionFinancial News Planner Backed By Experts - jammulinksnews.com
Pharvaris N.V. Shows Support at Fibonacci LevelStep-by-Step Trade Signal Implementation Guide Ready - metal.it
What markets is UKOMW expanding into Is Pharvaris N.V. stock a good long term investment optionStock Market Entry Points To Watch Now - jammulinksnews.com
How to integrate Pharvaris N.V. into portfolio analysis tools Short Term Opportunity Finder with Tools - Newser
How strong is Pharvaris N.V. company’s balance sheetUnlock your trading potential today - jammulinksnews.com
What is the risk reward ratio of investing in Pharvaris N.V. stockUnlock daily market insights for better decisions - jammulinksnews.com
What is the dividend policy of Pharvaris N.V. stockConsistently exceptional gains - jammulinksnews.com
Is Pharvaris N.V. a growth stock or a value stockCapitalize on emerging investment opportunities - jammulinksnews.com
What is Pharvaris N.V. company’s growth strategyFree Advanced Stock Screener Access - jammulinksnews.com
Pharvaris Announces US$201.2 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
New Product Launches: Will They Boost Pharvaris N.V. Stock in 2025Free Predictions - metal.it
Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions - Yahoo.co
Pharvaris N.V. Stock Performance After Earnings: Historical InsightsFree Access to Community - Newser
How Resilient Is Pharvaris N.V. Stock During Economic DownturnsHigh Return Potential - Newser
What analysts say about Pharvaris N.V. stockRecord-setting profit potential - Autocar Professional
Pharvaris' $201.2M Funding: A Strategic Catalyst for HAE Treatment Innovation and Shareholder Value - AInvest
Pharvaris N.V. Stock Analysis and ForecastDynamic investment opportunities - PrintWeekIndia
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):